In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

Noninferior five-year regional recurrence rates and regional recurrence-free survival reported with omission of SLNB.

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

The personalised cancer drug is based on the same technology as the leading coronavirus vaccines that helped end the pandemic ...

One large study found that more advanced cases of colorectal cancer had a higher likelihood of returning. For example, if participants had stage 3 colon cancer, almost 25 percent experienced a ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

What Is Recurrent Endometrial Cancer? Endometrial cancer is a type of cancer that starts in the lining of the uterus, called the endometrium. It's the most common form of gynecologic cancer in the ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...